Premarin WHI Results May Mean Additional Label Changes, FDA Says
The findings could lead FDA to revise the class labeling for hormone therapies to reflect the absence of risk of heart disease and invasive breast cancer among estrogen-only patients.
The findings could lead FDA to revise the class labeling for hormone therapies to reflect the absence of risk of heart disease and invasive breast cancer among estrogen-only patients.